References |
1 |
Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence
|
2 |
Effects of methamphetamine and its primary human metabolite, p-hydroxymethamphetamine, on the development of the Australian blowfly Calliphora stygia
|
3 |
Identification of new urinary metabolites of famprofazone in humans
|
4 |
Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
|
5 |
Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices Clin Pharmacokinet. 2004;43(3):157-85. doi: 10.2165/00003088-200443030-00002.
|
6 |
Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
|
7 |
Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine
|
8 |
Metabolism of ( 14 C)methamphetamine in man, the guinea pig and the rat
|
9 |
Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50.
|
10 |
Metabolic fate of fenetylline in rat and man
|
11 |
DrugBank(Pharmacology-Metabolism)Amphetamine
|